Pharsight

Actelion patents expiration

1. Opsumit patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7094781 ACTELION Sulfamides and their use as endothelin receptor antagonists
Dec, 2025

(1 year, 5 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10946015 ACTELION Stable pharmaceutical compositions comprising a pyrimidine-sulfamide
Sep, 2026

(2 years from now)

US9265762 ACTELION Stable pharmaceutical compositions comprising a pyrimidine-sulfamide
May, 2027

(2 years from now)

US8367685 ACTELION Stable pharmaceutical compositions comprising a pyrimidine-sulfamide
Oct, 2028

(4 years from now)

US8268847 ACTELION Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor
Apr, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 18, 2018
Orphan Drug Exclusivity(ODE) Oct 18, 2020
Orphan Drug Exclusivity(ODE-54) Oct 18, 2020

Drugs and Companies using MACITENTAN ingredient

NCE-1 date: 18 October, 2017

Market Authorisation Date: 18 October, 2013

Treatment: Method of treating pulmonary arterial hypertension by administering a pharmaceutical composition comprising macitentan and a polysorbate, wherein the polysorbate represents 0.1 to 1% of the weight of ...

Dosage: TABLET;ORAL

How can I launch a generic of OPSUMIT before it's drug patent expiration?
More Information on Dosage

OPSUMIT family patents

Family Patents

2. Tracleer patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5292740 ACTELION Sulfonamides
Nov, 2015

(8 years ago)

US8309126 ACTELION Dispersible bosentan tablet
May, 2026

(1 year, 10 months from now)

US7959945 ACTELION Dispersible bosentan tablet
Dec, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
ODE*(ODE*) Sep 05, 2024
New Patient Population(NPP) Sep 05, 2020
New Indication(I-607) Aug 07, 2012

Drugs and Companies using BOSENTAN ingredient

Market Authorisation Date: 20 November, 2001

Treatment: NA

Dosage: TABLET;ORAL; TABLET, FOR SUSPENSION;ORAL

How can I launch a generic of TRACLEER before it's drug patent expiration?
More Information on Dosage

TRACLEER family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Uptravi patents expiration

UPTRAVI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7205302 ACTELION Heterocyclic compound derivatives and medicines
Oct, 2026

(2 years from now)

US8791122 ACTELION Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same
Aug, 2030

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9173881 ACTELION Therapeutic compositions containing macitentan
Aug, 2029

(5 years from now)

US9284280 ACTELION Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide
Jun, 2030

(6 years from now)

US10828298 ACTELION Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide
Dec, 2036

(12 years from now)

US10821108 ACTELION Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide
Dec, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-106) Dec 21, 2022
Orphan Drug Exclusivity(ODE) Dec 21, 2022
New Chemical Entity Exclusivity(NCE) Dec 21, 2020

Drugs and Companies using SELEXIPAG ingredient

NCE-1 date: 22 December, 2019

Market Authorisation Date: 21 December, 2015

Treatment: Method of treating pulmonary arterial hypertension comprising administering selexipag in combination with the endothelin receptor antagonist macitentan; Method of treating pulmonary arterial hypertens...

Dosage: TABLET;ORAL; POWDER;INTRAVENOUS

How can I launch a generic of UPTRAVI before it's drug patent expiration?
More Information on Dosage

UPTRAVI family patents

Family Patents

4. Veletri patents expiration

VELETRI's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8598227 ACTELION Epoprostenol formulation and method of making thereof
Feb, 2027

(2 years from now)

US8318802 ACTELION Epoprostenol formulation and method of making thereof
Mar, 2027

(2 years from now)

Drugs and Companies using EPOPROSTENOL SODIUM ingredient

Market Authorisation Date: 28 June, 2012

Treatment: NA

Dosage: INJECTABLE;INJECTION

How can I launch a generic of VELETRI before it's drug patent expiration?
More Information on Dosage

VELETRI family patents

Family Patents

5. Zavesca patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5472969 ACTELION Method of inhibiting glycolipid synthesis
May, 2013

(11 years ago)

US5525616 ACTELION Method of inhibiting glycolipid synthesis
Jun, 2013

(11 years ago)

Drugs and Companies using MIGLUSTAT ingredient

Market Authorisation Date: 31 July, 2003

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

ZAVESCA family patents

Family Patents